Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing–Remitting Multiple Sclerosis
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 29 patients with relapsing-remitting multiple sclerosis who were taking interferon beta-1a injections
- Dose used in the study
- 600 mg a day of ultramicronised palmitoylethanolamide, added to interferon
- Duration
- 12 months
- What was measured
- Pain and redness at the injection site, quality of life, disability score, and blood levels of inflammatory cytokines
What the authors reported
Pain at the injection site was lower at 6 and 12 months than with placebo, quality of life scores were better, and interferon-gamma, TNF-alpha and IL-17 were lower. Plasma levels of palmitoylethanolamide, anandamide and oleoylethanolamide rose compared with placebo. Skin redness did not differ and disability scores did not progress in either group, with no adverse events during treatment.
Limits of this study
29 patients. The trial tested relief of a side effect of interferon injections. It was not designed to test an effect on the disease. The authors note the small sample and the lack of MRI data. Funding was not visible on the page checked.
Source
PubMed 26857391 · doi:10.1007/s13311-016-0420-z
Entry checked against the abstract on PubMed, and the article page at the publisher (Springer) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.